|
Thursday's hot stocks
|
 |
January 13, 2000: 2:20 p.m. ET
Incyte Pharmaceuticals, Synbiotics climb ahead
|
NEW YORK (CNNfn) - A drug firm and a supplier of diagnostic products for the animals both posted strong gains Thursday. On the downside, a retailer and a hardware supplier sank amid earnings woes.
Incyte Pharmaceuticals, Inc. (INCY) advanced 17 percent. The Palo Alto, Calif.-based drug firm said Biogen, Inc. (BGEN), a drug developer, would gain access to its database and software for viewing genes in the drug discovery process.
Incyte rose 17-1/16 to 120-1/16, and Cambridge, Mass.-based Biogen added 3-7/16 to 77-3/8.
Another Nasdaq component also performed well. Synbiotics Corp. (SBIO), a leading supplier of veterinary diagnostic products, soared 32 percent following its acquisition of W3Commerce, a privately held, San Diego-based Internet service provider.
San Diego, Calif.-based Synbiotics rose 13/16 to 3-3/8.
But Tommy Hilfiger Corp. (TOM) sank 18 percent. The Hong Kong-based clothing firm warned Thursday its fiscal third-quarter earnings will fall to between 58 and 64 cents per diluted share, significantly below analysts' forecasts of 73 cents.
Following the profit warning, both Morgan Stanley Dean Witter and Merrill Lynch downgraded their ratings on the stock.
Tommy Hilfiger fell 3-1/2 to 15-11/16.
Network Equipment Technologies Inc. (NWK) also suffered, falling 11 percent. A supplier of hardware and software used in network and communication devices, the company reported late Wednesday a third-quarter loss of 93 cents per share against analysts' estimates of an 18-cent loss.
Fremont, Calif.-based Network Equipment declined by 1-1/4 to 10-1/4.
Seattle FilmWorks Inc. (FOTO) jumped 15 percent. The company, which markets film and photo processing services to customers through the Internet, benefited from an alliance with AT&T WorldNet service in which WorldNet members can access their digital photos on Seattle FilmWorks service.
Seattle, Wash.-based Seattle FilmWorks rose 1/2 to 3-15/16.
A medical device maker, Lifecore Biomedical Inc. (LCBM) saw its shares plummet 64 percent after a Food and Drug Administration panel voted not to approve its application to sell its surgical adhesion product, Intergel, in the United States.
Chaska, Minn.-based Lifecore retreated 14-1/2 to 8. 
|
|
|
|
|
 |
|
